Loading...
Market
NASH resolution percentage in Phase 3 trial for VK2809 by end of 2025?
2
Resolution / Starting Odds
Less than 60% • 25%
60-70% • 25%
70-80% • 25%
More than 80% • 25%
Viking Therapeutics' clinical trial results publication
Story
Viking Therapeutics Reports Positive Phase 2b Results for VK2809 in NASH Patients: 75% NASH Resolution, 57% Fibrosis Improvement
Jun 4, 2024, 11:08 AM
Viking Therapeutics (VKTX) has announced positive results from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed Non-Alcoholic Steatohepatitis (NASH). The study revealed that up to 75% of patients treated with VK2809 achieved NASH resolution with no worsening of fibrosis, compared to 29% for the placebo group. Additionally, 57% of VK2809-treated patients achieved a one-stage improvement in fibrosis with no worsening of NASH. These results highlight VKTX's superior efficacy and safety profile compared to competitors, such as Madrigal Pharmaceuticals (MDGL). VKTX's safety profile is comparable to placebo, with no discontinuations reported, unlike GPCR, which has shown a high incidence of vomiting (62%) and study discontinuations. VKTX is also targeting the obesity market, showing impressive results with 6.2% weight loss and a significant potential for market growth.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Q3 2024 • 25%
Q4 2024 • 25%
H1 2025 • 25%
H2 2025 • 25%
Phase 4 trial • 25%
Approval in additional markets • 25%
Development of new formulations • 25%
Strategic partnership or collaboration • 25%
Progression-Free Survival (PFS) • 33%
Overall Survival (OS) • 33%
Both PFS and OS • 33%
80-90% success • 50%
Below 80% success • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Positive results • 33%
Neutral results • 34%
Negative results • 33%